Tumor News and Research

RSS

Franziska Michor named winner of Creative Promise Prize in Biomedical Science

Franziska Michor was picked as the winner of a Creative Promise Prize in Biomedical Science for her research that fuses evolutionary biology, mathematics, and clinical research toward a better understanding of cancer genesis and treatments.

12 Feb 2015

UT Southwestern gets NCI grant to establish Heavy Ion Radiation Therapy Research Center in US

UT Southwestern Medical Center is leading a Texas consortium of researchers to establish the country's first National Center for Heavy Ion Radiation Therapy that could provide clinical care and research using heavy particles for innovative new cancer treatments.

12 Feb 2015

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from the Food and Drug Administration for one of its lead candidates, antinuclear antibody (ANA) conjugated liposomal doxorubicin.

11 Feb 2015

FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

Amgen announced today that the Cellular, Tissue and Gene Therapies Advisory Committee and the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration will jointly review the Company's Biologics License Application (BLA) for talimogene laherparepvec.

11 Feb 2015

UT Southwestern leads researchers to establish National Center for Heavy Ion Radiation Therapy

11 Feb 2015

Research findings could lead to new standard of care for soft tissue sarcomas

Using advanced imaging technology to more precisely target radiation beams to treat soft tissue cancers (sarcomas) in the extremities significantly reduces long term side effects without effecting survival rates, according to research results published online today in the Journal of Clinical Oncology.

11 Feb 2015

GenomeDx announces publication of positive validation study for Decipher Prostate Cancer Classifier

GenomeDx Biosciences today announced the publication of a positive validation study for the Decipher® Prostate Cancer Classifier, a genomic test for prostate cancer. The study, published in the Journal of Clinical Oncology, showed that patients with low genomic risk (as determined by Decipher) may be optimally managed with observation after radical prostatectomy (prostate surgery), while those with high genomic risk (as determined by Decipher) may be better managed earlier with adjuvant radiotherapy.

10 Feb 2015

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chiasma Inc., a U.S. privately-held biopharma company, announced today that results from a multicenter Phase III study of the investigational new drug, octreotide capsules, were published online for early release on Feb. 9, ahead of print, by the Journal of Clinical Endocrinology & Metabolism.

10 Feb 2015

Study describes novel screening system that has potential to uncover effective ovarian cancer drugs

University of Chicago Medicine researchers have built a model system that uses multiple cell types from patients to rapidly test compounds that could block the early steps in ovarian cancer metastasis. Their three-dimensional cell-culture system, adapted for high-throughput screening, has enabled them to identify small molecules that can inhibit adhesion and invasion, preventing ovarian cancers from spreading to nearby tissues.

10 Feb 2015

Drug similar to Gleevec may help tame some brain cancers

The drug Gleevec (imatinib mesylate) is well known not only for its effectiveness against chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, but also for the story behinds its development. The drug was specifically designed to target an abnormal molecule--a fusion of two normal cell proteins--that fueled a tumor's growth.

10 Feb 2015

Roche announces acquisition of Signature Diagnostics

Roche announced today the acquisition of Signature Diagnostics AG, a privately held company based in Potsdam, Germany. Signature is a translational oncology and genomics company that develops large blood plasma and tissue biobanks in multiple cancers, including colorectal and lung, which are constructed from multicenter prospective clinical studies.

From Roche Sequencing and Life Science 10 Feb 2015

Scientists find that collagen 'cross-links' can determine tumor's ability to grow and spread

When skyscrapers go up, contractors rely on an infrastructure of steel beams and braces. Some cancers grow the same way, using a biological matrix from which the tumor can thrive and spread.

10 Feb 2015

Drugs designed to target NHE9 protein could help fight glioblastoma

Applying lessons learned from autism to brain cancer, researchers at The Johns Hopkins University have discovered why elevated levels of the protein NHE9 add to the lethality of the most common and aggressive form of brain cancer, glioblastoma. Their discovery suggests that drugs designed to target NHE9 could help to successfully fight the deadly disease.

10 Feb 2015

Discovery leads to new understanding of cancer metastasis

In a breakthrough in the understanding of how cancer spreads, researchers at the University of Virginia School of Medicine have identified a substance secreted by lung cancer cells that enables them to metastasize, beginning their deadly march to other sites in the body.

10 Feb 2015

Researchers discover inherited genetic variations associated with treatment-related hearing loss

St. Jude Children's Research Hospital investigators have discovered inherited genetic variations that are associated with rapid hearing loss in young cancer patients treated with the drug cisplatin. The research appears in the current online issue of the scientific journal Nature Genetics.

10 Feb 2015

Cancer researchers find important clues to why tumor cells become 'good' or 'bad'

For the first time, Keck Medicine of the University of Southern California cancer researchers have traced the origins of colorectal cancer cells, finding important clues to why tumor cells become "good" or "bad," with the potential of stopping them before they start.

10 Feb 2015

Scientists potentially discover new therapeutic targets to halt progression of tumor cells

Chronic inflammation is directly associated with several types of cancer, yet the reasons as to why this happens at a cellular level remain unclear. Now, an international team of scientists led by researchers at The Wistar Institute has identified a multistep process showing not only how these cancers develop but also potentially discovering new therapeutic targets that could halt the formation and progression of tumor cells.

10 Feb 2015

Combination therapies may overcome resistance to targeted cancer drugs

A protein called YAP, which drives the growth of organs during development and regulates their size in adulthood, plays a key role in the emergence of resistance to targeted cancer therapies, according to a new study led by UC San Francisco researchers.

10 Feb 2015

Only 65% of breast cancer patients who undergo mastectomy receive postmastectomy radiation therapy

Breast cancer patients who undergo a mastectomy should receive subsequent radiation treatment if their cancer has spread to four or more nearby lymph nodes, however, according to a new study, only 65 percent of these women are getting the recommended postmastectomy radiation therapy (PMRT).

10 Feb 2015

Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration ("FDA") for REOLYSIN® for the treatment of high grade gliomas (HGG) in pediatric patients.

9 Feb 2015

Tumor News and Research

Franziska Michor named winner of Creative Promise Prize in Biomedical Science

UT Southwestern gets NCI grant to establish Heavy Ion Radiation Therapy Research Center in US

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

UT Southwestern leads researchers to establish National Center for Heavy Ion Radiation Therapy

Research findings could lead to new standard of care for soft tissue sarcomas

GenomeDx announces publication of positive validation study for Decipher Prostate Cancer Classifier

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Study describes novel screening system that has potential to uncover effective ovarian cancer drugs

Drug similar to Gleevec may help tame some brain cancers

Roche announces acquisition of Signature Diagnostics

Scientists find that collagen 'cross-links' can determine tumor's ability to grow and spread

Drugs designed to target NHE9 protein could help fight glioblastoma

Discovery leads to new understanding of cancer metastasis

Researchers discover inherited genetic variations associated with treatment-related hearing loss

Cancer researchers find important clues to why tumor cells become 'good' or 'bad'

Scientists potentially discover new therapeutic targets to halt progression of tumor cells

Combination therapies may overcome resistance to targeted cancer drugs

Only 65% of breast cancer patients who undergo mastectomy receive postmastectomy radiation therapy

Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News